Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the eight analysts that are presently covering the stock, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $36.50.
Several analysts recently issued reports on the stock. Wedbush reissued an "outperform" rating and issued a $31.00 price target on shares of Bicara Therapeutics in a research report on Thursday, March 27th. HC Wainwright dropped their price target on shares of Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating on the stock in a research report on Monday. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.01 price objective on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Finally, Stifel Nicolaus set a $48.00 target price on Bicara Therapeutics in a research report on Thursday, March 27th.
Get Our Latest Research Report on Bicara Therapeutics
Hedge Funds Weigh In On Bicara Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in BCAX. California State Teachers Retirement System purchased a new stake in shares of Bicara Therapeutics during the 4th quarter worth approximately $25,000. Spire Wealth Management purchased a new stake in Bicara Therapeutics in the fourth quarter worth $31,000. BNP Paribas Financial Markets bought a new stake in shares of Bicara Therapeutics in the fourth quarter valued at $32,000. Legal & General Group Plc purchased a new position in shares of Bicara Therapeutics during the 4th quarter valued at $33,000. Finally, Summit Investment Advisors Inc. bought a new position in shares of Bicara Therapeutics during the 4th quarter worth $35,000.
Bicara Therapeutics Trading Down 4.1 %
NASDAQ:BCAX traded down $0.43 during trading hours on Friday, reaching $9.97. The company had a trading volume of 97,597 shares, compared to its average volume of 469,729. The business's 50-day simple moving average is $12.84 and its two-hundred day simple moving average is $17.03. Bicara Therapeutics has a twelve month low of $8.91 and a twelve month high of $28.09.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.08). Analysts expect that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.
About Bicara Therapeutics
(
Get Free ReportBicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Recommended Stories
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
